- Home
- NUVB vs BRSP Comparison
NUVB vs BRSP Comparison
Compare NUVB & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- BRSP
- Stock Information
- Founded
- NUVB 2018
- BRSP 2017
- Country
- NUVB United States
- BRSP United States
- Employees
- NUVB N/A
- BRSP N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- BRSP Real Estate Investment Trusts
- Sector
- NUVB Health Care
- BRSP Real Estate
- Exchange
- NUVB Nasdaq
- BRSP Nasdaq
- Market Cap
- NUVB 959.2M
- BRSP 806.6M
- IPO Year
- NUVB N/A
- BRSP 2018
- Fundamental
- Price
- NUVB $2.67
- BRSP $5.98
- Analyst Decision
- NUVB Strong Buy
- BRSP Hold
- Analyst Count
- NUVB 6
- BRSP 5
- Target Price
- NUVB $6.33
- BRSP $7.06
- AVG Volume (30 Days)
- NUVB 2.7M
- BRSP 487.8K
- Earning Date
- NUVB 11-06-2024
- BRSP 10-29-2024
- Dividend Yield
- NUVB N/A
- BRSP 10.72%
- EPS Growth
- NUVB N/A
- BRSP N/A
- EPS
- NUVB N/A
- BRSP N/A
- Revenue
- NUVB $2,162,000.00
- BRSP $378,095,000.00
- Revenue This Year
- NUVB N/A
- BRSP N/A
- Revenue Next Year
- NUVB N/A
- BRSP N/A
- P/E Ratio
- NUVB N/A
- BRSP N/A
- Revenue Growth
- NUVB N/A
- BRSP N/A
- 52 Week Low
- NUVB $1.43
- BRSP $5.07
- 52 Week High
- NUVB $4.16
- BRSP $8.01
- Technical
- Relative Strength Index (RSI)
- NUVB 48.20
- BRSP 39.87
- Support Level
- NUVB $2.51
- BRSP $6.22
- Resistance Level
- NUVB $2.87
- BRSP $6.37
- Average True Range (ATR)
- NUVB 0.17
- BRSP 0.16
- MACD
- NUVB -0.02
- BRSP -0.07
- Stochastic Oscillator
- NUVB 30.77
- BRSP 31.11
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.